Research progress on chemical composition and clinical efficacy of Lianhua Qingwen (LHQW) capsule, a traditional Chinese medicine (TCM) used to treat COVID-19
10.12206/j.issn.1006-0111.202011002
- VernacularTitle:抗新冠肺炎中药连花清瘟胶囊化学成分与临床功效研究进展
- Author:
Yuanye ZENG
1
;
Yingying HE
1
;
Qinglong TANG
2
;
Kang LI
3
;
Yanqiu GU
4
;
Xiaofei CHEN
1
Author Information
1. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. Former Organ Out-patient Department of Political Work Department of Central Military Commission, Beijing 100120, China.
3. Medical Service Department, General Hospital of Southern Theater Command, Guangzhou 510010, China.
4. Department of Pharmacy, Ninth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 201999, China.
- Keywords:
COVID-19;
Lianhua Qingwen capsule;
pharmacological activity
- From:
Journal of Pharmaceutical Practice
2021;39(4):291-294
- CountryChina
- Language:Chinese
-
Abstract:
The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19.
